image credit- shutterstock
Sigachi Industries Limited, a leading player in the pharmaceutical industry, is strengthening its research and development (R&D) capabilities with a $1 million investment in a state-of-the-art R&D centre in Hyderabad. This initiative aims to bring API development and analytical efforts under one roof, optimising production processes and driving innovation.
The new facility will play a crucial role in enhancing API synthesis, streamlining the pharma product portfolio, and ensuring adherence to stringent global regulatory standards.
Sigachi is intensifying its R&D investments to drive high-value innovation, with plans to fuel additional 6 CEP (Certification of Suitability) filing over the next six months. The centre will also house a team of 15-20 experienced R&D scientists dedicated to accelerating product development for regulated markets. By allowing synergies for manufacturing cutting-edge APIs and regulatory filings under the same roof, Sigachi is positioning itself for sustained growth, increased efficiency, and market leadership.
This investment aims to reinforce Sigachi’s commitment to innovation and long-term profitability, ensuring the company remains at the forefront of pharmaceutical advancements. The project is set to commence immediately.
